Brought to you by 
Three investors buy $7.4mm in Aposense stock
07 Dec 2010
Executive Summary
Concurrent with its $15mm IPO on the Tel Aviv Stock Exchange, Aposense Ltd. (primarily cancer compounds that image apoptosis in vivo) netted NIS28.5mm ($7.4mm) by selling 1.02mm ordinary shares to returning shareholders Ziegler Meditech and Pontifax Group, and new backer Leumi Partners. The investors also received 253.9k Series 1 warrants and 507.7k Series 2 warrants.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Three investors buy $7.4mm in Aposense stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice